Explore Guideview's Agri & Industry articles! Stay updated with the latest news, policies, and scientific insights relevant to the agriculture & industry.
Axalta 2024 Financial ReportFinancial statements
AxaltaAxalta's 2024 sales in China reached 4.1 billion RMB, driven by strong demand in the automotive and new energy vehicle markets. The company experienced significant growth, marking a historical high for the region.
Nippon Paint 2024 Financial ReportFinancial statements
NipponNippon Paint China achieved a 13% revenue growth in 2024, reaching 545.2 billion yen. Strong sales in automotive, industrial, and architectural coatings drove growth, despite challenges in the real estate sector. The company aims for further expansion in 2025.
Jotun's 2024 Financial ReportFinancial statements
JotunJotun's revenue grew by 7.4% to $3.2 billion in 2024, with strong sales momentum across all segments. The company expects continued growth in 2025 despite economic uncertainties, focusing on profitability and cost control amid competitive market conditions.
Behr's 2024 Financial ReportFinancial statements
Masco
BehrMasco's Behr paint business generated $2.505 billion in 2024, with PRO paint sales growing and DIY sales declining. Despite a 5% segment revenue drop, operating margins improved. Masco expects steady 2025 growth, focusing on efficiency, acquisitions, and capital returns.
Axalta's 2024 Financial ResultsFinancial statements
AxaltaAxalta reports record 2024 sales of $5.3 billion, with a 45% increase in net profit. Strong performance in automotive and light vehicle coatings led to impressive growth, alongside robust transformation initiatives and favorable pricing.
Kansai Paint's Q3 Financial ResultsFinancial statements
Kansai PaintKansai Paint's Q3 2025 report reveals a 5.3% sales increase to ¥444.75 billion but a 39% drop in net profit. The company revises full-year guidance, citing economic challenges in key markets like India, Europe, and Asia.
By a Narrow Margin, Kennedy Jr. Wins Approval!HHSThe U.S. Senate Finance Committee approves Robert F. Kennedy Jr.'s nomination for HHS Secretary by a narrow margin, despite vaccine concerns. His confirmation vote now heads to the full Senate for final approval.